Q9Y233 (PDE10_HUMAN) Homo sapiens (Human)

cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A UniProtKBInterProSTRINGInteractive Modelling

779 aa; Sequence (Fasta) ; (Isoform 2; ) Identical sequences: Homo sapiens: A0A1B1UZR0; Gorilla gorilla gorilla: G3QMU8

Sequence Features

Add
 515Proton donor
 519Divalent metal cation 1
 553Divalent metal cation 1
 554Divalent metal cation 1
 554Divalent metal cation 2
 664Divalent metal cation 1
 97Y -> C (in IOLOD; decreased protein abundance; dbSNP:rs778899140) VAR_076798 dbSNP
 106A -> P (in IOLOD; decreased protein abundance; dbSNP:rs875989839) VAR_076799 dbSNP
 290F -> L (in ADSD2; no effect on basal 3',5'-cyclic- nucleotide phosphodiesterase activity; the mutation severely disrupts the stimulatory effect on the enzyme activity mediated by cAMP binding; dbSNP:rs875989841) VAR_076800 dbSNP
 303L -> P VAR_008797
 324F -> L (in ADSD2; no effect on basal 3',5'-cyclic- nucleotide phosphodiesterase activity; the mutation severely disrupts the stimulatory effect on the enzyme activity mediated by cAMP binding; dbSNP:rs875989840) VAR_076801 dbSNP
 706R -> K (in dbSNP:rs2224252) VAR_047822 dbSNP
 707D -> N (in dbSNP:rs2860112) VAR_047823 dbSNP
 94-215GAF domain
IPR003018PF01590
 267-412GAF domain
IPR003018PF01590
 514-7453'5'-cyclic nucleotide phosphodiesterase, catalytic domain
IPR002073PF00233

Sequence Alignments

Experimental structures

DescriptionOligo-stateLigandsStructureRange
Crystal Structure of PDE10A with a biaryl ether inhibitor (1-(1-(3-(4-(benzo[d]thiazol-2-ylamino)ph…homo-3-mer ZN; 24×SO4;GOL;15H;4hf4442-759
Assess
Crystal Structure of PDE10A with a biaryl ether inhibitor ((1-(3-(4-((1H-benzo[d]imidazol-2-yl)amin…homo-3-mer ZN; 18×SO4;15J;4heu442-759
Assess
PDE10a Crystal Structure Complexed with Novel Inhibitorhomo-3-mer ZN; 21×SO4;0JQ;4ddl442-759
Assess
Crystal Structure of PDE10A with Imidazo[4,5-b]pyridines as Potent and Selective Inhibitorshomo-3-mer ZN; 36×SO4; 15×GOL;2KR;4p1r442-759
Assess
Crystal structure of PDE10a with a novel Imidazo[4,5-b]pyridine inhibitorhomo-3-mer 1IS;1IR;ZN;SO4;GOL;4p0n453-759
Assess
2-(3-alkoxy-1-azetidinyl) quinolines as novel PDE10A inhibitorshomo-3-mer ZN; 21×SO4;GOL;35D;4tpp453-757
Assess
Crystal structure of 2-(3-alkoxy-1-azetidinyl) quinolines as PDE10A Inhibitorshomo-3-mer 21×SO4;GOL;35E;ZN;4tpm454-756
Assess
Identification and structural characterization of PDE10 fragment inhibitorshomo-2-mer ZN;MG;F03;4ajf439-764
Assess
2-[2-(4-Phenyl-1H-imidazol-2-yl)ethyl]quinoxaline (Sunovion Compound 14) co-crystallized with PDE10Ahomo-2-mer ZN;MG;4F7;4yqh439-759
Assess
PDE10 complexed with 4-isopropoxy-2-(2-(3-(4-methoxyphenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)…homo-2-mer ZN;MG;4PX;4Q0;4zo5439-759
Assess
Co-crystal structure of 2-[2-(5,8-dimethyl[1,2,4]triazolo[1,5-a]pyrazin-2-yl)ethyl]-3-methyl-3H-imi…homo-2-mer ZN;MG;4GK;4ys7439-759
Assess
Crystal Structure of PDE10A with Novel Keto-Benzimidazole Inhibitorhomo-2-mer ZN; 15×SO4;GOL;2F4;4muw442-759
Assess
Crystal structure of the catalytic domain of PDE10A complexed with 1-(2-fluoro-4-(1H-pyrazol-1-yl)p…homo-2-mer MG;ZN;3K9;3wym445-759
Assess
Crystal structure of the catalytic domain of PDE10A complexed with 3-(1-phenyl-1H-pyrazol-5-yl)-1-(…homo-2-mer MG;ZN;3KG;3wyk445-759
Assess
Crystal Structure of PDE10A with Novel Keto-Benzimidazole Inhibitorhomo-2-mer ZN; 12×SO4;2F5;4mvh452-759
Assess
Crystal Structure of PDE10A with 1H-benzimidazol-2-yl(4-((3-(tetrahydro-2H-pyran-4-yl)-2-pyridinyl)…homo-2-mer ZN;SO4;2W1;4phw454-758
Assess
Crystal structure of the C-terminal GAF domain of human phosphodiesterase 10Ahomo-2-mer CMP;2zmf246-422
Assess
Crystal structure of PDE10A2 with fragment ZT450monomer 7ZE;NI;4lm1439-767
Assess
Crystal structure of PDE10A2 with fragment ZT464monomer 9ZE;NI;EDO;4lm3439-766
Assess
crystal structure of pde10a2 mutant D564A in complex with cAMP.monomer ZN;MG;CMP;2ouy439-766
Assess
Crystal structure of PDE10A2 with fragment ZT902monomer JPZ;NI;4lm4439-765
Assess
Crystal structure of PDE10A2 with fragment ZT217monomer MEW;NI;4llk439-765
Assess
Crystal structure of PDE10A2 with fragment ZT462monomer 8ZE;NI;4lm2439-765
Assess
Crystal structure of PDE10A2 with fragment ZT214monomer 1XN;NI;4llj439-765
Assess
Crystal structure of PDE10A2 with fragment ZT0429 (4-methyl-3-nitropyridin-2-amine)monomer 2ZV;NI;4mrz439-765
Assess
Crystal structure of PDE10A2 with fragment ZT0449 (5-nitro-1H-benzimidazole)monomer 2ZM;NI;4msa439-765
Assess
Crystal structure of PDE10A2 with fragment ZT017monomer 1XM;NI;4lkq439-765
Assess
Crystal structure of PDE10A2 with fragment ZT448monomer 5NI;NI;4lm0439-765
Assess
Crystal structure of PDE10A2 with fragment ZT434monomer 5ZE;NI;4llx439-765
Assess
Crystal structure of PDE10A2 with fragment ZT401monomer 4ZE;NI;4llp439-765
Assess
Crystal structure of PDE10A2 with fragment ZT0443 (6-chloropyrimidine-2,4-diamine)monomer 2ZX;NI;4ms0439-765
Assess
Crystal structure of PDE10A2 with fragment ZT0120 (7-chloroquinolin-4-ol)monomer MRW;NI;4mrw439-765
Assess
Crystal structure of PDE10A2 with fragment ZT0451 (8-nitroquinoline)monomer 2ZQ;NI;4msn439-765
Assess
Crystal structure of PDE10A2 with fragment ZT1595 (2-[(quinolin-7-yloxy)methyl]quinoline)monomer 2ZT;NI;4msc439-765
Assess
Crystal structure of PDE10A2 with fragment ZT1597 (2-({[(2S)-2-methyl-2,3-dihydro-1,3-benzothiazol-…monomer 2ZU;NI;4mse439-765
Assess
crystal structure of PDE10A2 mutant D674A in complex with cGMPmonomer MG;35G;2ouu439-764
Assess
Novel, potent, selective and brain penetrant phosphodiesterase 10A inhibitorsmonomer ZN;MG;JY4;6msa439-764
Assess
Crystal Structure of PDE10A2 with fragment ZT0143 ((2S)-4-chloro-2,3-dihydro-1,3-benzothiazol-2-ami…monomer 2D0;NI;4msh439-764
Assess
crystal structure of PDE10A2 in complex with GMPmonomer ZN;MG;5GP;2ouq439-762
Assess
Human PDE-papaverine complex obtained by ligand soaking of cross- linked protein crystalsmonomer EV1;ZN;MG;2wey437-760
Assess
crystal structure of PDE10A2 mutant D674Amonomer MG;2ous439-761
Assess
PDE10 complexed with 6-chloro-2-cyclopropyl-5-methyl-pyrimidin-4-aminemonomer ZN;MG;4XV;5c28439-761
Assess
crystal structure of pde10a2 mutant of D564Nmonomer ZN;MG;2ouv439-761
Assess
PDE10 complexed with 4,6-dichloro-2-cyclopropyl-5-methyl-pyrimidinemonomer ZN;MG;4XS;5c1w439-761
Assess
PDE10 complexed with N-[(1-methylpyrazol-4-yl)methyl]-5-[[(1S,2S)-2-(2-pyridyl)cyclopropyl]methoxy]…monomer ZN;MG;5AY;5dh5448-770
Assess
crystal structure of PDE10A2 mutant D674A in complex with cAMPmonomer MG;CMP;2our439-760
Assess
crystal structure of PDE10Amonomer ZN;MG;2oup439-760
Assess
crystal structure of PDE10A2 in complex with AMPmonomer ZN;MG;AMP;2oun439-760
Assess
Crystal structure of PDE10A in complex with ASP9436monomer ZN;MG;490;4xy2439-760
Assess
Crystal structure of PDE10A in complex with inhibitormonomer ZN;MG;P98;3wi2439-760
Assess
Identification and structural characterization of PDE10 fragment inhibitorsmonomer ZN;MG;F04;4ajd439-760
Assess
Crystal structure of PDE10A in complex with a triazolopyrimidine inhibitormonomer ZN;MG;D6X;6kdx439-760
Assess
Crystal structure of PDE10A in complex with a benzimidazole inhibitormonomer ZN;MG;X4C;3ws8439-760
Assess
Crystal structure of PDE10 in complex with inhibitor 2bmonomer ZN;MG;6iji439-760
Assess
Crystal structure of PDE10A catalytic domain complexed with LHB-6monomer ZN;MG;9G6;5znl439-760
Assess
Crystal structure of PDE10A in complex with a triazolopyrimidine inhibitormonomer ZN;MG;D7C;6ke0439-760
Assess
Crystal structure of PDE10A in complex with a benzimdazole inhibitormonomer ZN;MG;X4D;3ws9439-760
Assess
Crystal structure of PDE10A in complex with a triazolopyrimidine inhibitormonomer ZN;MG;D79;6kdz439-760
Assess
Crystal structure of PDE10A in complex with 1-methyl-5-(1-methyl-3-{[4-(quinolin-2-yl)phenoxy]methy…monomer ZN;MG;3SJ;4wn1439-760
Assess
Highly Potent, Selective, and Orally Active Phosphodiestarase 10A Inhibitorsmonomer CL;540;ZN;MG;3sn7439-759
Assess
Highly Potent, Selective, and Orally Active Phosphodiestarase 10A Inhibitorsmonomer ZN;MG;CL;546;3sni439-759
Assess
PDE10 complexed with 6-chloro-2-cyclopropyl-N-[(2,4-dimethylthiazol-5-yl)methyl]-5-methyl-pyrimidin…monomer ZN;MG;4Y2;5c2a439-759
Assess
Potent and Selective Phosphodiesterase 10A Inhibitorsmonomer ZN;MG;0T6;4fcd439-759
Assess
PDE10 complexed with6-chloro-N-[(2,4-dimethylthiazol-5-yl)methyl]-5-methyl-2-[2-(2-pyridyl)ethoxy]p…monomer ZN;MG;4PX;5c2e439-759
Assess
Potent and Selective Phosphodiesterase 10A Inhibitorsmonomer ZN;MG;0T7;4fcb439-759
Assess
Novel, potent, selective and brain penetrant phosphodiesterase 10A inhibitorsmonomer ZN;MG;JY7;6msc439-759
Assess
Highly Potent, Selective, and Orally Active Phosphodiestarase 10A Inhibitorsmonomer ZN;MG;3snl439-759
Assess
Crystal structure of PDE10A in complex with 7-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]pyrimidinemonomer ZN;MG;8G6;5xuj439-759
Assess
Crystal structure of PDE10A in complex with 2-methyl-5-[2-([1,2,4]triazolo[1,5-a]pyrimidin-2-yl)et …monomer ZN;MG;8G3;5xui439-759
Assess
Crystal structure of human PDE10A in complex with inhibitor 16dmonomer 8Q7;ZN;MG;5uwf439-758
Assess
PDE10 complexed with 6-chloro-N-[(2,4-dimethylthiazol-5-yl)methyl]-5-methyl-2-[3-(2-quinolyl)propox…monomer ZN;MG;4XU;5c2h439-758
Assess
Identification and structural characterization of PDE10 fragment inhibitorsmonomer ZN;MG;F07;4ajg439-758
Assess
Crystal structure of PDE10 in complex with inhibitor AF-399/14387019monomer ZN;MG;AEO;6ijh439-758
Assess
PDE10A in complex with the inhibitor AZ5monomer ZN;MG;4HN;4ael439-757
Assess
Development of a plate-based optical biosensor methodology to identify PDE10 fragment inhibitorsmonomer ZN;MG;4ajm439-756
Assess
Crystal structure of the catalytic domain of PDE10A complexed with highly potent and brain-penetran…monomer MG;ZN;4LP;5axq445-759
Assess
Crystal structure of the catalytic domain of PDE10A complexed with 1-(2-fluoro-4-(2-oxo-1,3-oxazoli…monomer MG;ZN;4LK;5axp445-759
Assess
Discovery of orally active pyrazoloquinoline as a potent PDE10 inhibitor for the management of schi…monomer C1L;MG;ZN;3ui7446-760
Assess
Crystal structure of the catalytic domain of human PDE10A complexed with 1-(cyclopropylmethyl)-5-(2…monomer MG;ZN;6DW;5b4l445-759
Assess
Crystal structure of the catalytic domain of PDE10A complexed with 5-methoxy-3-(1-phenyl-1H-pyrazol…monomer ZN;MG;3KB;3wyl445-759
Assess
Crystal structure of the catalytic domain of human PDE10A complexed with N-(4-((5-methyl-5H-pyrrolo…monomer MG;ZN;6DT;5b4k445-759
Assess
human PDE10A in complex with 1-(4-Chloro-phenyl)-3-methyl-1H-thieno[2,3-c]pyrazole-5-carboxylic aci…monomer ZN;MG;GOL;5M6;5ede447-760
Assess
Triazoloquinazolines as a novel class of phosphodiesterase 10A (PDE10A) inhibitors, part 2, Lead-op…monomer AXC;ZN;MG;2y0j446-759
Assess
human PDE10A, 6-Chloro-5,8-dimethyl-2-[2-(2-methyl-5-pyrrolidin-1-yl-2H-[1,2,4]triazol-3-yl)-ethyl]…monomer ZN;MG;5M9;5edi448-760
Assess
human PDE10A in complex with 3-(2-Chloro-5-phenyl-3H-imidazol-4-yl)-1-(3-trifluoromethoxy-phenyl)-1…monomer ZN;MG;5MG;5edg448-760
Assess
human PDE10A in complex with 3-(2-phenylpyrazol-3-yl)-1-[3-(trifluoromethoxy)phenyl]pyridazin-4-onemonomer ZN;MG;67A;5i2r448-760
Assess
human PDE10A, 8-ethyl-5-methyl-2-[2-(2-methyl-5-pyrrolidin-1-yl-1,2,4-triazol-3-yl)ethyl]-[1,2,4]tr…monomer ZN;MG;5MF;5edh449-760
Assess
The crystal structue of PDE10A complexed with 14monomer ZN;MG;DZU;7bpi448-759
Assess
Discovery of a potent, selective and orally active PDE10A inhibitor for the treatment of schizophre…monomer LKF;ZN;MG;4bbx448-759
Assess
PDE10a with imidazopyrazine inhibitormonomer ZN;MG;6RC;5k9r448-759
Assess
The crystal structue of PDE10A complexed with 2dmonomer ZN;MG;DL0;6ko1450-759
Assess
The crystal structue of PDE10A complexed with 1imonomer DKU;ZN;MG;6ko0452-759
Assess
PDE10 complexed with 6-chloro-2-cyclopropyl-5-methyl-N-propyl-pyrimidin-4-aminemonomer ZN;MG;4XY;5c29454-760
Assess
The SAR development of dihydroimidazoisoquinoline derivatives as phosphodiesterase 10A inhibitors f…monomer MG;ZN;4dff453-759
Assess
PDE10 complexed with 5-chloro-N-[(2,4-dimethylthiazol-5-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-aminemonomer ZN;MG;5AV;4PX;5dh4451-757
Assess
The crystal structue of PDE10A complexed with 4dmonomer DZU;ZN;MG;6kze453-758
Assess
The discovery of potent, selectivity, and orally bioavailable pyrozoloquinolines as PDE10 inhibitor…monomer 0CV;MG;ZN;PO4;3uuo455-759
Assess

Homology models

Oligo-stateQMEANTemplateRangeSeq id (%)Ligands
monomer -4.31 1mc0.1.A73-426
27.83
Assess

Homology models built on isoform sequence

IsoformOligo-stateLigandsQMEANTemplateRangeSeq id (%)
Isoform 2monomer-3.701mc0.1.A99-436
28.53
Assess
Isoform 2monomer-4.956mzb.1.B30-770
25.75
Assess